Insights · Pharma & medicinal products
GMP-Compliant Translation: What pharmaceutical companies need to know
GMP-compliant translation means: Documentation that stands up to inspection in every language version.
What the GMP guidelines mean for translations
In the EU, GMP (Good Manufacturing Practice) sets out, through the EU-GMP Guideline (EudraLex Volume 4) and Directive (EU) 2017/1572, how medicinal products must be manufactured and documented. Chapter 4 of the guideline requires complete, unambiguous and traceable documentation, from the work instruction through to the batch record. A GMP-compliant translation renders these documents into the target language so that accuracy, consistent terminology and the traceability of every processing step are fully preserved. This is achieved with qualified specialised translators, a documented review process and verifiable quality assurance. In a GMP environment, an inaccurate translation is a documentation deficiency, with consequences for marketing authorisation, inspections and patient safety.
Which pharma documents are translated
SOPs & manufacturing directives
Standard operating procedures and manufacturing specifications for international locations and contract manufacturers.
Batch records
Batch records and reports, forming the evidence layer of GMP documentation.
Marketing authorisation: SmPC, package leaflet, labelling
Product information based on the EMA QRD templates, in all EU/EEA languages under the centralised procedure.
Specifications & validation
Test specifications, certificates of analysis, and qualification and validation documents.
Audit, inspection and CAPA documentation
Audit reports, regulatory authority correspondence, deviation and CAPA documentation.
Training materials
GMP training and hygiene requirements for employees in the local language.
We cover safety data sheets (SDS) and REACH/CLP documents on the industry page. Pharmaceuticals & Chemicals.
Why in-house translation poses a compliance risk
'Our QA team translates it on the side' or 'the local site handles it' is understandable, but risky in a GMP environment. Three pitfalls:
Marketing authorisation and inspection
The pharmaceutical company is liable for the accuracy of the documentation. Discrepancies between language versions may be regarded as a documentation deficiency during inspections and can even result in objections during the marketing authorisation procedure.
Lack of an audit trail
GMP documentation relies on traceability. Without a documented, qualified translation process, it is impossible to demonstrate the diligence of the language version during an audit. “Done in-house” does not constitute verifiable quality assurance.
Terminology & patient safety
In manufacturing instructions, package leaflets and warning notices, precision is crucial. Inconsistent terminology or careless mistakes can result in misuse, with consequences for patient safety and liability.
The regulatory framework at a glance
EudraLex Volume 4
The EU GMP guideline. Chapter 4 governs documentation: Instructions and records that are complete and traceable.
Directive (EU) 2017/1572
Principles and guidelines of Good Manufacturing Practice for medicinal products for human use.
Directive 2001/83/EC (Art. 63)
The labelling and package leaflet must be provided in the official language or languages of the Member State in which the medicinal product is placed on the market.
EMA: QRD & linguistic review
Product information in line with QRD templates in all EU/EEA languages. Translations must be submitted five calendar days after the CHMP opinion and are reviewed by the Member States.
GDP guidelines (2013/C 343/01)
Good Distribution Practice: wholesale distributors also require a fully documented quality system.
AMWHV and ICH guidelines
In Germany, the AMWHV (the German Ordinance on the Manufacture of Medicinal Products and Active Substances) sets out GMP requirements in detail; internationally, ICH guidelines such as Q7 (active substances) supplement the framework.
Keeping track of developments
- The EU is renewing its pharmaceutical legislation: Political agreement on the EU pharmaceutical package was reached in December 2025. The final texts were published in March 2026, and final adoption is expected in autumn 2026. It will replace Directive 2001/83/EC and Regulation (EC) No 726/2004, with transitional periods for implementation.
- Electronic product information (ePI) and digital dossiers are on the rise, and with them the volume and frequency of multilingual content.
- The EU GMP guideline is continuously revised (most recently including Annex 1 on sterile manufacturing). Documentation and data integrity requirements remain a core focus of inspections.
Status as of July 2026; information without guarantee. The applicable EU legislation and the national requirements of the target markets are binding.
Pharmaceutical translations that stand up to inspections
From SOPs to package leaflets, following ISO 17100 processes, with specialised translators and transparent, well-documented quality assurance.
An audit-ready translation process at COMLOGOS
COMLOGOS translates pharmaceutical documentation in accordance with ISO 17100 processes (certified): Specialised translators with a pharmaceutical and scientific background, a mandatory four-eyes principle, consistent terminology and clear documentation of every step in the translation process. Where artificial intelligence adds value, we use it in a controlled way with human post-editing in accordance with ISO 18587 (certified). Industry context: Pharmaceuticals & Chemicals, and for medical devices instead of medicinal products: MDR/IVDR-compliant translation.
Technologies used
Frequently asked questions about GMP compliant translations
What does GMP-compliant translation mean?
A translation that meets the documentation requirements of Good Manufacturing Practice: produced by qualified specialised translators, checked in line with the four-eyes principle, with consistent terminology and a clearly documented process. GMP does not prescribe any specific translation method, but it does require documentation to be correct, unambiguous and traceable in every language version.
Which pharmaceutical documents need to be translated?
Typical examples include standard operating procedures (SOPs) and manufacturing instructions for international sites, batch documentation, the product information of the marketing authorisation (SmPC, package leaflet, labelling), specifications and validation documents, as well as audit, inspection and CAPA documentation and training material.
In which language must the package leaflet and the labelling be available?
In accordance with Article 63 of Directive 2001/83/EC, in the official language or languages of the Member State in which the medicinal product is placed on the market. In the centralised marketing authorisation procedure, the product information is translated into all EU/EEA languages in line with the EMA QRD templates and must be submitted five calendar days after the CHMP opinion. The information is provided without any guarantee.
What do the GMP guidelines require with regard to documentation?
Chapter 4 of the EU GMP Guideline (EudraLex Volume 4) requires complete, clear and traceable documentation. This is divided into instructions (such as SOPs) and records (such as protocols) and must be maintained in accordance with the principles of good documentation practice. These requirements apply accordingly to every language version: An incorrect translation constitutes a documentation deficiency.
Can the translation be done internally or by the foreign subsidiary?
The regulations do not specify who is responsible for carrying out the translation. However, the pharmaceutical company remains responsible for the accuracy of every language version. Without a qualified, documented process, due care cannot be demonstrated during an audit, and discrepancies between language versions may be assessed as a documentation deficiency. A certified process in accordance with ISO 17100 reduces this risk.
Is it permitted to produce pharmaceutical translations using AI?
Artificial intelligence can support the process when it is used in a controlled manner and combined with human post-editing in line with ISO 18587. Qualified human expert review and documented quality assurance remain crucial, especially for manufacturing instructions, package leaflets and safety‑critical content.
What changes does the EU pharmaceutical package introduce for translations?
The EU pharmaceutical package is the most extensive reform of European medicinal product legislation in more than twenty years. Following the political agreement in December 2025, the final texts were published in March 2026. Formal adoption by the Council and Parliament is expected in 2026. It replaces Directive 2001/83/EC and Regulation (EC) No 726/2004, subject to transitional periods. For translations, this primarily means: Product information and marketing authorisation documents will be adjusted throughout the implementation phase, in a consistent manner across all language versions. Consistently maintained terminology and an up-to-date Translation Memory keep the effort involved in these adaptations manageable. The information is provided without guarantee; the applicable EU legal acts in force at the time are authoritative.
What our clients in the pharmaceutical and medical technology sectors say
Regulated, review-required specialised translation, validated by manufacturers from the pharmaceutical and medical technology sectors.
"For many years, we have been relying on COMLOGOS’s competent support for regulatory translations. We particularly value the high quality of the translations, the reliability and the flexibility when working to demanding schedules. The professional and straightforward collaboration gives us confidence that even time-critical projects are completed on schedule and to a high professional standard."
"We are very satisfied with the fast and straightforward processing of our orders and with the friendly and competent support from our team. Our complex medical texts are translated with a high level of professionalism and care. We appreciate the ongoing collaborative partnership with COMLOGOS."
Request a project & receive expert advice
Would you like to have SOPs, registration documents or batch documentation translated in a GMP compliant translation process? Please send us 1–2 sample files. You will receive a specific recommendation and a quote within 24 hours.
